title: Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation.
abstract: It has been suggested that cystic fibrosis (CF) patients harboring multiresistant (MR) Pseudomonas aeruginosa (PA) should be seen in separate clinics. The aim of this study was to test the feasibility of this by longitudinally studying the consistency of isolates of MRPA in individuals. We analyzed all respiratory tract cultures undertaken in 1 year from a pediatric CF clinic population (n = 367). PA was classified as MR according to the definition of the American CF Foundation: resistance to all agents in at least two of the following groups of antibiotics: beta-lactams, aminoglycosides, and fluroquinolones. PA was cultured from 96 children during the year of study. Thirty-six were infected with at least one MR strain. Following initial identification of MRPA, MR in subsequent cultures was highly variable. Twenty-three of 36 patients had subsequent cultures in which PA was identified. However, 21 of 23 patients had at least one isolate that was not MR following detection of MRPA. The variability with time in isolation of MR strains from individuals demonstrates the potential difficulties in designing segregation policies based on antibiotic sensitivity patterns.
authors.affiliation: Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Trust, London, UK.
authors.forename: G
authors.initials: G
authors.lastname: Davies
authors.forename: D
authors.initials: D
authors.lastname: McShane
authors.forename: J C
authors.initials: JC
authors.lastname: Davies
authors.forename: A
authors.initials: A
authors.lastname: Bush
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000517:prevention & control*; D003550:Cystic Fibrosis / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D005240:Feasibility Studies; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000150:complications / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification*